The Institute for Clinical and Economic Review on Aug. 1 released a Draft Scoping Document as it prepares to review the comparative clinical effectiveness and value of Novartis’ canakinumab for reducing cardiovascular risk in atherosclerosis patients.
According to a press release, the document is open for public comment until 5 p.m. EST Aug. 22.
Canakinumab was approved by the U.S. Food and Drug Administration in 2009 and is on the market for a number of inflammatory conditions. The treatment is reportedly being reviewed for a new indication in atherosclerosis.
ICER’s California Technology Assessment Forum will review the canakinumab report in February 2019, according to the release.